Rozita Mohd

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani et al. · The Lancet · 2023 · 151 citations · Full text

Hypertension, Renal Function, Renal Disease +10

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 88 citations · Full text

Persistent hypertension in lupus nephritis and the associated risk factors

S. S. Shaharir, Ruslinda Mustafar, Rozita Mohd et al. · Clinical Rheumatology · 2014 · 60 citations

Glomerular Disease, Glomerulonephritis, Hypertension +15

Damage in the Multiethnic Malaysian Systemic Lupus Erythematosus (SLE) Cohort: Comparison with Other Cohorts Worldwide

Syahrul Sazliyana Shaharir, Heselynn Hussein, Rajalingham Sakthiswary et al. · PLoS ONE · 2016 · 44 citations · Full text

Systemic Diseases, Psoriatic Arthritis, Sle Patients +22

Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: a 6-months open-label, randomized controlled trial

Mohd Noor Azreey Mukri, Wei Yen Kong, Ruslinda Mustafar et al. · PubMed · 2018 · 44 citations · Full text